Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 11, November, p. 1483–1490

doi: 10.17219/acem/75499

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The impact of sitagliptin, inhibitor of dipeptidyl peptidase-4 (DPP-4), on the ADMA-DDAH-NO pathway in ischemic and reperfused rat livers

Małgorzata Trocha1,A,B,C,D,F, Beata Nowak1,C,E, Anna Merwid-Ląd1,D, Andrzej Szuba2,3,C, Piotr Dzięgiel4,5,E, Małgorzata Pieśniewska1,B, Agnieszka Gomułkiewicz4,B, Jerzy Wiśniewski6,C, Tomasz Piasecki7,B, Magdalena Gziut1,D, Adam Szeląg1,E,F, Tomasz Sozański1,C,E

1 Department of Pharmacology, Faculty of Medicine, Wroclaw Medical University, Poland

2 Department of Internal Medicine, 4th Military Hospital with Policlinic, Wrocław, Poland

3 Department of Internal Nursing, Faculty of Health Sciences, Wroclaw Medical University, Poland

4 Department of Histology and Embryology, Faculty of Medicine, Wroclaw Medical University, Poland

5 Department of Histology and Embryology, Poznan University of Medical Sciences, Poland

6 Department of Medical Biochemistry, Faculty of Medicine, Wroclaw Medical University, Poland

7 Department of Epizootiology and Clinic of Bird and Exotic Animals, Wroclaw University of Environmental and Life Sciences, Poland

Abstract

Background. A correlation between the level of asymmetric dimethylarginine (ADMA) – the inhibitor of the nitric oxide (NO) synthesis – and the liver function and survival after a liver transplantation has been reported.
Objectives. The aim of this study was to evaluate the effect of sitagliptin –the inhibitor of dipeptidyl peptidase-4 (DPP-4) – on the NO-ADMA-dimethylarginine dimethylaminohydrolase (DDAH) pathway in rat livers subjected to ischemia/reperfusion (IR).
Material and Methods. The rats received sitagliptin (5 mg/kg, per os – p.o.) (groups: S – livers not subjected to IR procedure, and SIR – livers subjected to IR procedure) or a saline solution (groups: C – livers not subjected to IR procedure, and CIR – livers subjected to IR procedure) for 14 days; following this, livers in the SIR and CIR groups were subjected to ischemia (60 min) and reperfusion (24 h). Aminotransferases were measured before the surgery; additionally, the arginine (ARG), ADMA and symmetric dimethylarginine (SDMA) levels were estimated just before ischemia and during reperfusion (at 0.5, 4 and 24 h). After IR, citrulline, the DDAH activity, mRNA for type 1 DDAH (DDAH1), and arginine methyltransferase type 1 (PRMT1) were determined.
Results. The increase in the initial level of ARG/ADMA0 (A/A) ratio in group S compared to group C verged on statistical significance. At 0.5 and 4 h of reperfusion, the highest concentration of ADMA was found in group CIR. At those time points, the ARG level and the A/A ratio were decreased in groups CIR and SIR as compared to groups C and S, respectively. The alanine transaminase (ALT) activity was lower in the sitagliptin-treated group than in the non-treated one. The DDAH and citrulline levels were reduced in group CIR as compared to group C, but were greater in group SIR as compared to group S. The PRMT1 mRNA expression was higher in groups CIR and SIR, compared to groups C and S, respectively.
Conclusion. The increased A/A ratio suggests a protective effect of sitagliptin on livers not subjected to IR. Changes in the DDAH activity and the PRMT1 mRNA expression also imply the protective activity of sitagliptin during IR.

Key words

liver, rat, ischemia/reperfusion, asymmetric dimethylarginine, sitagliptin

References (38)

  1. Maslak E, Gregorius A, Chlopicki S. Liver sinusoidal endothelial cells (LSECs) function and NAFLD: NO-based therapy targeted to the liver. Pharmacol Rep. 2015;67(4):689–694.
  2. Langer DA, Shah VA. A gas, an amino acid, and an imposter: The story of nitric oxide, L-arginine, and ADMA in portal hypertension. Hepatology. 2005;42(6):1255–1257.
  3. Mòdol T, Natal C, Pérez de Obanos MP, et al. Apoptosis of hepatic stellate cells mediated by specific protein nitration. Biochem Pharmacol. 2011;81(3):451–458.
  4. Buttery LD, Springall DR, Chester AH, et al. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest. 1996; 75(1):77–85.
  5. Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl. 2003;4(4):33–40.
  6. Fan C, Zwacka RM, Engelhardt JF. Therapeutic approaches for ischemia/reperfusion injury in the liver. J Mol Med. 1999;77(8):577–596.
  7. Hines IN, Harada H, Flores S, Gao B, McCord JM, Grisham MB. Endothelial nitric oxide synthase protects the post-ischemic liver: Potential interactions with superoxide. Biomed Pharmacother. 2005;59(4):183–189.
  8. Martin-Sanz P, Olmedilla L, Dulin E, et al. Presence of methylated arginine derivatives in orthotopic human liver transplantation: Relevance for liver function. Liver Transpl. 2003;9(1):40–48.
  9. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: Dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol. 2004;24(6):1023–1030.
  10. Deacon CF. Dipeptidyl peptidase 4 inhibition with sitagliptin: A new therapy for type 2 diabetes. Expert Opin Investig Drugs. 2007;16(4):533–545.
  11. Vaghasiya J, Sheth N, Bhalodia Y, Manek R. Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Regulatory Peptides. 2011;166(1–3):48–54.
  12. Chen YT, Tsai TH, Yang CC, et al. Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J Transl Med. 2013;11:270–289.
  13. Wolfgang J, Ingrid DM, Veerle M, et al. Inhibition of CD26/DPP IV attenuates ischemia/reprfuson injury in orthotopic mouse lung transplants: The pivotal role of vasoactive intestinal peptide. Peptides. 2010;31:585–591.
  14. Morales AI, Vicente-Sanchez C, Jerkic M, et al. Effect of quercetin on metallothionein, nitric oxide synthase and cyclooxygenase-2 expression on experimental chronic cadmium nephrotoxicity in rats. Toxicol Appl Pharmacol. 2006;210(1–2):128–135.
  15. Trocha M, Merwid-Ląd A, Chlebda-Sieragowska E, et al. Age-related changes in ADMA-DDAH NO pathway in rat liver subjected to partial ischemia followed by global reperfusion. Exp Gerontol. 2014;50:45–51.
  16. Wiśniewski J, Fleszar MG, Piechowicz J, et al. A novel mass spectrometry-based method for simultaneous determination of asymmetric and symmetric dimethylarginine, l-arginine and l-citrulline optimized for LC-MS-TOF and LC-MS/MS. Biomed Chromatogr. 2017;31:1–11. doi: 10.1002/bmc.3994
  17. Bode-Böger SM, Scalera F, Kielstein JT, et al. Symmetrical dimethylarginine: A new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol. 2006;17(4):1128–1134.
  18. Gore MO, Lüneburg N, Schwedhelm E, et al. Symmetrical dimethylarginine predicts mortality in the general population: Observations from the Dallas heart study. Arterioscler Thromb Vasc Biol. 2013; 33(11):2682–2688.
  19. Nijveldt RJ, Teerlink T, Siroen MP, et al. Elevation of asymmetric dimethylarginine (ADMA) in patients developing hepatic failure after major hepatectomy. JPEN J Parenter Enteral Nutr. 2004;28(6):382–387.
  20. Lorin J, Zeller M, Guilland JC, Cottin Y, Vergely C, Rochette L. Arginine and nitric oxide synthase: Regulatory mechanisms and cardiovascular aspects. Mol Nutr Food Res. 2014;58(1):101–116.
  21. Nguyen MC, Park JT, Jeon YG, et al. Arginase inhibition restores peroxynitrite-induced endothelial dysfunction via L-arginine-dependent endothelial nitric oxide synthase phosphorylation. Yonsei Med J. 2016;57(6):1329–1338.
  22. Pope AJ, Karuppiah K, Cardounel AJ. Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production. Pharmacol Res. 2009;60(6):461–465.
  23. Hornig B, Arakawa N, Böger RH, Bode-Böger SM, Frölich JC, Drexler H. Plasma levels of ADMA are increased and inversely related to endothelium-mediated vasodilation in patients with chronic heart failure: A new predictor of endothelial dysfunction? Circulation. 1998; 98(Suppl 1):318.
  24. Dimitrow PP, Undas A, Bober M, Tracz W, Dubiel JS. Plasma biomarkers of endothelial dysfunction in patients with hypertrophic cardiomyopathy. Pharmacol Rep. 2007;59(6):715–720.
  25. Trocha M, Merwid-Ląd A, Sozański T, et al. Influence of ezetimibe on ADMA-DDAH-NO pathway in rat liver subjected to partial ischemia followed by global reperfusion. Pharmacol Rep. 2013;65(1):122–133.
  26. Trocha M, Merwid-Ląd A, Szuba A, et al. Effect of simvastatin on nitric oxide synthases (eNOS, iNOS) and arginine and its derivatives (ADMA, SDMA) in ischemia/reperfusion injury in rat liver. Pharmacol Rep. 2010;62(2):343–351.
  27. Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl. 2003;4(4):33–40.
  28. Ferrigno A, Di Pasqua LG, Berardo C, Richelmi P, Vairetti M. Liver plays a central role in asymmetric dimethylarginine-mediated organ injury. World J Gastroenterol. 2015;21(17):5131–5137.
  29. Maas R. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vasc Med. 2005;10(Suppl 1):S49–S57.
  30. Matsuguma K, Ueda S, Yamagishi S, et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol. 2006;17(8):2176–2183.
  31. Zhai W, Cardell M, De Meester I, et al. Ischemia/reperfusion injury: The role of CD 28/dipeptidyl-peptidase-IV-inhibition in lung transplantation. Transplant Proc. 2006;38(10):3369–3371.
  32. Chang MW, Chen CH, Chen YC, at al. Sitagliptin protects rat kidneys from acute ischemia-reperfusion injury via upregulation of GLP-1 and GLP-1 receptors. Acta Pharmacol Sin. 2015;36(1):119–130.
  33. Trocha M, Merwid-Ląd A, Szuba A, Sozański T, Magdalan J, Szeląg A. Asymmetric dimethylarginine synthesis and degradation under physiological and pathological conditions. Adv Clin Exp Med. 2010; 19(2):223–243.
  34. Vaghasiya JD, Sheth NR, Bhalodia YS, Jivani NP. Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: Effect of exenatide. Saudi J Gastroenterol. 2010;16(3):174–180.
  35. Toyoda-Akui M, Yokomori H, Kaneko F, et al. A case of drug-induced hepatic injury associated with sitagliptin. Intern Med. 2011;50(9):1015–1020.
  36. Gross BN, Cross LB, Foard J, Wood Y. Elevated hepatic enzymes potentially associated with sitagliptin. Ann Pharmacother. 2010;44(2):394–395.
  37. Raz I, Hanefel M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564–2571.
  38. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194–205.
© Wroclaw Medical University